Liveome
Seoul, South Korea· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
South Korean biotech developing precision microbiome diagnostics and therapeutics for metabolic diseases through advanced genomic analysis.
Metabolic
Technology Platform
Proprietary microbiome sequencing and bioinformatics platform that analyzes gut microbial composition and function to identify biomarkers and therapeutic targets for metabolic disorders.
Opportunities
Growing global interest in microbiome-based therapies, high prevalence of metabolic diseases in Asian populations, and potential for diagnostic-therapeutic combinations in personalized medicine.
Risk Factors
Scientific uncertainty in microbiome-disease causality, regulatory challenges for novel microbiome products, and intense competition in the rapidly evolving microbiome therapeutics space.
Competitive Landscape
Competes with Seres Therapeutics, Vedanta Biosciences, and Finch Therapeutics in microbiome therapeutics, and DayTwo in microbiome diagnostics, differentiated by focus on Asian metabolic disease populations and integrated diagnostic-therapeutic approach.